{"id":776682,"date":"2026-05-06T06:35:16","date_gmt":"2026-05-06T06:35:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/776682\/"},"modified":"2026-05-06T06:35:16","modified_gmt":"2026-05-06T06:35:16","slug":"weight-loss-drugs-like-ozempic-may-come-with-an-unexpected-cost","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/776682\/","title":{"rendered":"Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost"},"content":{"rendered":"

\"Woman<\/a>Glucagon-like peptide-1 (GLP-1) medications are drugs used to treat type 2 diabetes and support weight loss. They mimic a natural hormone that helps regulate blood sugar, slow digestion, and reduce appetite, leading to improved metabolic control. Credit: Shutterstock<\/p>\n

New research suggests that the promise of GLP-1 weight loss drugs is accompanied by an overlooked challenge: shifting, and sometimes intensified, social stigma.<\/strong><\/p>\n

GLP-1 drugs like Ozempic and Wegovy have rapidly transformed weight loss from a frustrating, often futile struggle into something that, for many, finally works.<\/p>\n

In the past few years, these medications have surged in popularity, with tens of millions of prescriptions written worldwide and an estimated 1 in 8 U.S. adults reporting they\u2019ve tried a GLP-1 drug at some point. Celebrities, executives, and everyday patients alike have embraced them, fueling what some call a new era of obesity treatment.<\/p>\n

But a new study from Rice University<\/a> suggests that the public reaction to these medications is not simply admiration or acceptance. In some situations, people who use them may face more criticism than those who do not lose weight at all.<\/p>\n

The research, led by Erin Standen, assistant professor of psychological sciences at Rice University and published in the International Journal of Obesity, reveals a striking pattern of bias. Co-authors include Sean Phelan of the Mayo Clinic and Janet Tomiyama of the University of California, Los Angeles.<\/p>\n

\u201cWe expected there might be some stigma around using a GLP-1,\u201d Standen said. \u201cBut what surprised us was the extent of it.\u201d<\/p>\n

Perceptions of Weight Loss Methods<\/p>\n

In the study, participants were asked to evaluate a fictional person based on their weight history. The individual either lost weight using a GLP-1 medication, lost weight through diet and exercise, or did not lose weight at all.<\/p>\n

The results showed a clear trend. People viewed those who used GLP-1 medications less favorably than those who lost weight through diet and exercise.<\/p>\n

More strikingly, participants rated GLP-1 users more negatively than individuals who had not lost weight at all.<\/p>\n

\"Cheery<\/a>Despite significant weight loss, new research suggests people may still face stigma\u2014depending on how they lost it. Credit: Shutterstock<\/p>\n

\u201cThe GLP-1 users were socially penalized not just compared to someone who lost weight through diet and exercise,\u201d Standen said. \u201cThey were also rated more harshly than someone who didn\u2019t lose weight in the first place.\u201d<\/p>\n

These findings suggest that weight-related stigma does not disappear after weight loss. Instead, it can shift depending on how the weight loss occurs.<\/p>\n

\u201cThere\u2019s this idea that if you lose weight, you might escape stigma,\u201d Standen said. \u201cBut what we\u2019re seeing is that people may face judgment at multiple points. They may be judged for their weight and for how they choose to manage it.\u201d<\/p>\n

As GLP-1 medications become more widely used, these perceptions may play a growing role.<\/p>\n

\u201cThere\u2019s a narrative that using these medications is \u2018taking the easy way out,\u2019\u201d Standen said. \u201cAnd that belief seems to shape how people are judged.\u201d<\/p>\n

What Happens When Weight Returns<\/p>\n

The researchers also examined what happens when people stop using GLP-1 medications. Many discontinue them because of cost, insurance limits, or side effects, and weight regain is common.<\/p>\n

The study found that individuals who regained weight, whether after using a GLP-1 drug or following a diet, were judged more negatively than those who lost weight and maintained it.<\/p>\n

\"Chubby<\/a>Participants in the study viewed weight loss through diet and exercise more favorably than weight loss achieved with medication. Credit: Stock<\/p>\n

\u201cThere\u2019s a lot of stigma tied to weight regain in general,\u201d Standen said. \u201cAnd that doesn\u2019t seem to depend much on how the weight was lost in the first place.\u201d<\/p>\n

Broader Health Implications<\/p>\n

Standen emphasized that these attitudes can have real health consequences. Weight stigma has been linked to stress, avoidance of medical care, and unhealthy coping behaviors.<\/p>\n

\u201cIf people feel judged for the choices they\u2019re making about their health, that can influence what they\u2019re willing to do,\u201d she said. \u201cIt can affect whether they seek care, whether they talk openly with providers and how they manage their health overall.\u201d<\/p>\n

This issue is especially important as GLP-1 medications continue to gain attention and use.<\/p>\n

\u201cThis is a moment where these treatments are really entering the mainstream,\u201d Standen said. \u201cSo understanding the social side of that is critical.\u201d<\/p>\n

Rethinking the Narrative Around Weight<\/p>\n

Standen\u2019s research is part of a broader effort to encourage healthier behaviors without reinforcing stigma. Her goal is to understand how people can make informed choices about their health without feeling judged.<\/p>\n

\u201cThere\u2019s such a strong cultural script around weight and what a \u2018healthy\u2019 body should look like,\u201d she said. \u201cAnd those messages can get in the way of people doing what\u2019s actually best for them.\u201d<\/p>\n

She hopes the findings will help shift public attitudes.<\/p>\n

\u201cUltimately, any form of stigma related to someone\u2019s body or their health choices is not helpful,\u201d Standen said. \u201cPeople should be able to make decisions that are right for them without fear of being judged.\u201d<\/p>\n

Reference: \u201cAn experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation\u201d by Erin C. Standen, Sean M. Phelan and A. Janet Tomiyama, 3 April 2026, International Journal of Obesity.
DOI: 10.1038\/s41366-026-02061-y<\/a><\/p>\n

Never miss a breakthrough: Join the SciTechDaily newsletter.<\/a><\/b>
Follow us on Google<\/a> and Google News<\/a>.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Glucagon-like peptide-1 (GLP-1) medications are drugs used to treat type 2 diabetes and support weight loss. They mimic…\n","protected":false},"author":3,"featured_media":776683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,10943,152,16382,15209,67,132,68,428],"class_list":{"0":"post-776682","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-obesity","11":"tag-pharmaceuticals","12":"tag-rice-university","13":"tag-semaglutide","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us","17":"tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116526247554334956","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/776682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=776682"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/776682\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/776683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=776682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=776682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=776682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}